Gilead Sciences Stock Revenue
| GILD Stock | USD 90.19 0.43 0.48% |
Gilead Sciences fundamentals help investors to digest information that contributes to Gilead Sciences' financial success or failures. It also enables traders to predict the movement of Gilead Stock. The fundamental analysis module provides a way to measure Gilead Sciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Gilead Sciences stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 27.1 B | 28.5 B |
Gilead | Revenue |
Gilead Sciences Company Revenue Analysis
Gilead Sciences' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Gilead Sciences Revenue | 27.12 B |
Most of Gilead Sciences' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Gilead Sciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Gilead
Projected quarterly revenue analysis of Gilead Sciences provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Gilead Sciences match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Gilead Sciences' stock price.
Gilead Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Gilead Sciences is extremely important. It helps to project a fair market value of Gilead Stock properly, considering its historical fundamentals such as Revenue. Since Gilead Sciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Gilead Sciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Gilead Sciences' interrelated accounts and indicators.
| -0.42 | -0.66 | 0.22 | -0.53 | -0.16 | ||
| -0.42 | 0.85 | -0.63 | 0.99 | 0.63 | ||
| -0.66 | 0.85 | -0.66 | 0.9 | 0.61 | ||
| 0.22 | -0.63 | -0.66 | -0.6 | -0.98 | ||
| -0.53 | 0.99 | 0.9 | -0.6 | 0.58 | ||
| -0.16 | 0.63 | 0.61 | -0.98 | 0.58 |
Click cells to compare fundamentals
Gilead Revenue Historical Pattern
Today, most investors in Gilead Sciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Gilead Sciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Gilead Sciences revenue as a starting point in their analysis.
Gilead Sciences Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Gilead Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Gilead Sciences reported 27.12 B of revenue. This is 255.54% higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The revenue for all United States stocks is 187.4% lower than that of the firm.
Gilead Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Gilead Sciences' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Gilead Sciences could also be used in its relative valuation, which is a method of valuing Gilead Sciences by comparing valuation metrics of similar companies.Gilead Sciences is currently under evaluation in revenue category among its peers.
Gilead Sciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Gilead Sciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Gilead Sciences' managers, analysts, and investors.Environmental | Governance | Social |
Gilead Sciences Institutional Holders
Institutional Holdings refers to the ownership stake in Gilead Sciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Gilead Sciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Gilead Sciences' value.| Shares | Bank Of New York Mellon Corp | 2024-06-30 | 14.1 M | Northern Trust Corp | 2024-09-30 | 12.5 M | Legal & General Group Plc | 2024-06-30 | 12.4 M | Dimensional Fund Advisors, Inc. | 2024-09-30 | 11.7 M | Amundi | 2024-06-30 | 11.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 10.6 M | Amvescap Plc. | 2024-06-30 | 10.1 M | Goldman Sachs Group Inc | 2024-06-30 | 9.2 M | Pacer Advisors, Inc. | 2024-06-30 | 7.9 M | Blackrock Inc | 2024-06-30 | 120.6 M | Vanguard Group Inc | 2024-09-30 | 115.3 M |
Gilead Fundamentals
| Return On Equity | 0.0056 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0 % | ||||
| Operating Margin | 0.42 % | ||||
| Current Valuation | 130.61 B | ||||
| Shares Outstanding | 1.25 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 88.37 % | ||||
| Number Of Shares Shorted | 17.74 M | ||||
| Price To Earning | 359.42 X | ||||
| Price To Book | 6.08 X | ||||
| Price To Sales | 3.97 X | ||||
| Revenue | 27.12 B | ||||
| Gross Profit | 21.62 B | ||||
| EBITDA | 7.61 B | ||||
| Net Income | 5.61 B | ||||
| Cash And Equivalents | 6.14 B | ||||
| Cash Per Share | 4.90 X | ||||
| Total Debt | 24.99 B | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 1.43 X | ||||
| Book Value Per Share | 14.83 X | ||||
| Cash Flow From Operations | 8.01 B | ||||
| Short Ratio | 3.50 X | ||||
| Earnings Per Share | 0.09 X | ||||
| Price To Earnings To Growth | 0.53 X | ||||
| Target Price | 96.89 | ||||
| Number Of Employees | 18 K | ||||
| Beta | 0.19 | ||||
| Market Capitalization | 112.4 B | ||||
| Total Asset | 62.12 B | ||||
| Retained Earnings | 16.3 B | ||||
| Working Capital | 4.8 B | ||||
| Current Asset | 1.18 B | ||||
| Current Liabilities | 104.89 M | ||||
| Annual Yield | 0.03 % | ||||
| Five Year Return | 3.76 % | ||||
| Net Asset | 62.12 B | ||||
| Last Dividend Paid | 3.06 |
About Gilead Sciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Gilead Sciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Gilead Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Gilead Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:Check out Gilead Sciences Piotroski F Score and Gilead Sciences Altman Z Score analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.42) | Dividend Share 3.06 | Earnings Share 0.09 | Revenue Per Share 22.703 | Quarterly Revenue Growth 0.07 |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.